25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CLVLF (Clinuvel) Stock Analysis
Buy, Hold or Sell?

Let's analyze Clinuvel together

I guess you are interested in Clinuvel Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Clinuvel’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Clinuvel’s Price Targets

I'm going to help you getting a better view of Clinuvel Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Clinuvel (30 sec.)










1.2. What can you expect buying and holding a share of Clinuvel? (30 sec.)

How much money do you get?

How much money do you get?
$0.19
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
$3.98
Expected worth in 1 year
$11.54
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$7.75
Return On Investment
107.4%

For what price can you sell your share?

Current Price per Share
$7.22
Expected price per share
$7.22 - $7.22
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Clinuvel (5 min.)




Live pricePrice per Share (EOD)
$7.22
Intrinsic Value Per Share
$2.70 - $10.09
Total Value Per Share
$6.68 - $14.07

2.2. Growth of Clinuvel (5 min.)




Is Clinuvel growing?

Current yearPrevious yearGrowGrow %
How rich?$203m$108.2m$94.7m46.7%

How much money is Clinuvel making?

Current yearPrevious yearGrowGrow %
Making money$35.6m$20.1m$15.5m43.5%
Net Profit Margin40.4%39.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Clinuvel (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#303 / 881

Most Revenue
#132 / 881

Most Profit
#60 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Clinuvel?

Welcome investor! Clinuvel's management wants to use your money to grow the business. In return you get a share of Clinuvel.

First you should know what it really means to hold a share of Clinuvel. And how you can make/lose money.

Speculation

The Price per Share of Clinuvel is $7.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Clinuvel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Clinuvel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.98. Based on the TTM, the Book Value Change Per Share is $1.89 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Clinuvel.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.709.7%0.709.7%0.395.4%0.506.9%0.456.3%0.283.8%
Usd Book Value Change Per Share1.8926.2%1.8926.2%-0.34-4.7%0.689.5%0.577.9%0.375.1%
Usd Dividend Per Share0.050.7%0.050.7%0.030.3%0.030.4%0.030.4%0.020.3%
Usd Total Gains Per Share1.9426.8%1.9426.8%-0.31-4.3%0.719.9%0.608.3%0.395.4%
Usd Price Per Share10.10-10.10-0.00-3.37-9.74-9.11-
Price to Earnings Ratio14.46-14.46-0.00-4.82-23.25-19.14-
Price-to-Total Gains Ratio5.21-5.21-5.21-32.87-27.09-
Price to Book Ratio2.54-2.54-0.00-0.85-5.08-8.54-
Price-to-Total Gains Ratio5.21-5.21-5.21-32.87-27.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.22
Number of shares138
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.03
Usd Book Value Change Per Share1.890.57
Usd Total Gains Per Share1.940.60
Gains per Quarter (138 shares)267.4882.31
Gains per Year (138 shares)1,069.90329.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1271043106016313319
2532086213032626648
3803130320048939977
4107417342706412531306
5134521653408015661635
6160625964109718791964
71877302748011321922293
82148345855012925052622
92419389962014528182951
10267104321069016131313280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%8.016.00.033.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%14.010.00.058.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.02.080.0%8.00.016.033.3%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%14.010.00.058.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Clinuvel Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.8901.8900%-0.336+118%0.682+177%0.567+233%0.367+415%
Book Value Per Share--3.9793.9790%2.089+90%2.831+41%2.377+67%1.490+167%
Current Ratio--8.8088.8080%7.438+18%8.8280%9.916-11%9.743-10%
Debt To Asset Ratio--0.1220.1220%0.150-19%0.133-9%0.117+4%0.115+5%
Debt To Equity Ratio--0.1380.1380%0.177-22%0.154-10%0.134+4%0.132+5%
Dividend Per Share--0.0480.0480%0.025+93%0.032+49%0.029+66%0.020+138%
Enterprise Value--671126089.300671126089.3000%--671126089.3000%921417345.990-27%626528528.700+7%
Eps--0.6980.6980%0.388+80%0.497+41%0.454+54%0.277+152%
Ev To Ebitda Ratio--11.92611.9260%--11.9260%40.440-71%27.186-56%
Ev To Sales Ratio--7.6117.6110%--7.6110%20.112-62%25.242-70%
Free Cash Flow Per Share--0.6170.6170%-0.013+102%0.198+211%0.112+450%0.116+432%
Free Cash Flow To Equity Per Share--0.5470.5470%-0.041+108%0.156+251%0.075+629%0.111+394%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.977+2%0.993+1%
Intrinsic Value_10Y_max--10.088----------
Intrinsic Value_10Y_min--2.699----------
Intrinsic Value_1Y_max--0.374----------
Intrinsic Value_1Y_min--0.154----------
Intrinsic Value_3Y_max--1.610----------
Intrinsic Value_3Y_min--0.566----------
Intrinsic Value_5Y_max--3.431----------
Intrinsic Value_5Y_min--1.088----------
Market Cap361438254.000-43%515369801.300515369801.3000%-+100%171789933.767+200%495352336.994+4%460266077.560+12%
Net Profit Margin--0.4040.4040%0.391+3%0.371+9%0.428-6%-0.041+110%
Operating Margin--0.6250.6250%0.623+0%0.602+4%0.556+13%-0.029+105%
Operating Ratio--0.4290.4290%0.437-2%0.443-3%0.478-10%1.052-59%
Pb Ratio1.815-40%2.5392.5390%-+100%0.846+200%5.076-50%8.543-70%
Pe Ratio10.338-40%14.46214.4620%-+100%4.821+200%23.245-38%19.135-24%
Price Per Share7.220-40%10.10010.1000%-+100%3.367+200%9.737+4%9.114+11%
Price To Free Cash Flow Ratio11.704-40%16.37316.3730%-+100%5.458+200%-448.048+2837%-216.625+1423%
Price To Total Gains Ratio3.725-40%5.2115.2110%--5.2110%32.866-84%27.086-81%
Quick Ratio--14.23014.2300%12.237+16%14.449-2%15.414-8%12.821+11%
Return On Assets--0.1540.1540%0.158-2%0.152+1%0.178-13%0.082+88%
Return On Equity--0.1760.1760%0.186-6%0.1760%0.201-13%0.083+111%
Total Gains Per Share--1.9381.9380%-0.311+116%0.715+171%0.596+225%0.387+400%
Usd Book Value--203011366.000203011366.0000%108228513.408+88%145599640.803+39%121840980.682+67%76028458.041+167%
Usd Book Value Change Per Share--1.8901.8900%-0.336+118%0.682+177%0.567+233%0.367+415%
Usd Book Value Per Share--3.9793.9790%2.089+90%2.831+41%2.377+67%1.490+167%
Usd Dividend Per Share--0.0480.0480%0.025+93%0.032+49%0.029+66%0.020+138%
Usd Enterprise Value--671126089.300671126089.3000%--671126089.3000%921417345.990-27%626528528.700+7%
Usd Eps--0.6980.6980%0.388+80%0.497+41%0.454+54%0.277+152%
Usd Free Cash Flow--31477667.00031477667.0000%-675499.537+102%10122576.488+211%5724915.693+450%5861384.346+437%
Usd Free Cash Flow Per Share--0.6170.6170%-0.013+102%0.198+211%0.112+450%0.116+432%
Usd Free Cash Flow To Equity Per Share--0.5470.5470%-0.041+108%0.156+251%0.075+629%0.111+394%
Usd Market Cap361438254.000-43%515369801.300515369801.3000%-+100%171789933.767+200%495352336.994+4%460266077.560+12%
Usd Price Per Share7.220-40%10.10010.1000%-+100%3.367+200%9.737+4%9.114+11%
Usd Profit--35636359.00035636359.0000%20119441.688+77%25544755.229+40%23601874.338+51%14298044.969+149%
Usd Revenue--88178308.00088178308.0000%51488434.453+71%68463011.484+29%57186008.091+54%36830652.345+139%
Usd Total Gains Per Share--1.9381.9380%-0.311+116%0.715+171%0.596+225%0.387+400%
 EOD+4 -4MRQTTM+0 -0YOY+28 -63Y+27 -75Y+26 -1410Y+32 -8

3.3 Fundamental Score

Let's check the fundamental score of Clinuvel Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.338
Price to Book Ratio (EOD)Between0-11.815
Net Profit Margin (MRQ)Greater than00.404
Operating Margin (MRQ)Greater than00.625
Quick Ratio (MRQ)Greater than114.230
Current Ratio (MRQ)Greater than18.808
Debt to Asset Ratio (MRQ)Less than10.122
Debt to Equity Ratio (MRQ)Less than10.138
Return on Equity (MRQ)Greater than0.150.176
Return on Assets (MRQ)Greater than0.050.154
Total9/10 (90.0%)

3.4 Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.844
Ma 20Greater thanMa 507.237
Ma 50Greater thanMa 1007.102
Ma 100Greater thanMa 2007.235
OpenGreater thanClose7.220
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-06-18 00:37:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Clinuvel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 40.4%Β means thatΒ $0.40 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 40.4%. The company is making a huge profit. +2
  • The TTM is 40.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ40.4%TTM40.4%0.0%
TTM40.4%YOY39.1%+1.3%
TTM40.4%5Y42.8%-2.4%
5Y42.8%10Y-4.1%+46.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ40.4%-91.7%+132.1%
TTM40.4%-139.0%+179.4%
YOY39.1%-194.4%+233.5%
3Y37.1%-248.5%+285.6%
5Y42.8%-343.3%+386.1%
10Y-4.1%-488.9%+484.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Clinuvel is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 15.4% Return on Assets means thatΒ Clinuvel generatedΒ $0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 15.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 15.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%YOY15.8%-0.4%
TTM15.4%5Y17.8%-2.4%
5Y17.8%10Y8.2%+9.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4%-11.6%+27.0%
TTM15.4%-11.7%+27.1%
YOY15.8%-11.4%+27.2%
3Y15.2%-11.9%+27.1%
5Y17.8%-12.1%+29.9%
10Y8.2%-13.8%+22.0%
4.3.1.3. Return on Equity

Shows how efficient Clinuvel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 17.6% Return on Equity means Clinuvel generated $0.18Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 17.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 17.6%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ17.6%TTM17.6%0.0%
TTM17.6%YOY18.6%-1.0%
TTM17.6%5Y20.1%-2.5%
5Y20.1%10Y8.3%+11.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.6%-13.5%+31.1%
TTM17.6%-15.0%+32.6%
YOY18.6%-14.5%+33.1%
3Y17.6%-16.9%+34.5%
5Y20.1%-17.9%+38.0%
10Y8.3%-19.9%+28.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Clinuvel Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Clinuvel is operatingΒ .

  • Measures how much profit Clinuvel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • An Operating Margin of 62.5%Β means the company generated $0.63 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 62.5%. The company is operating very efficient. +2
  • The TTM is 62.5%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ62.5%TTM62.5%0.0%
TTM62.5%YOY62.3%+0.3%
TTM62.5%5Y55.6%+7.0%
5Y55.6%10Y-2.9%+58.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ62.5%-229.2%+291.7%
TTM62.5%-249.7%+312.2%
YOY62.3%-208.4%+270.7%
3Y60.2%-221.7%+281.9%
5Y55.6%-344.1%+399.7%
10Y-2.9%-470.4%+467.5%
4.3.2.2. Operating Ratio

Measures how efficient Clinuvel is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.43 means that the operating costs are $0.43 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.429. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.429. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.429TTM0.4290.000
TTM0.429YOY0.437-0.008
TTM0.4295Y0.478-0.049
5Y0.47810Y1.052-0.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4292.108-1.679
TTM0.4292.680-2.251
YOY0.4373.080-2.643
3Y0.4433.621-3.178
5Y0.4784.734-4.256
10Y1.0526.546-5.494
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Clinuvel Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Clinuvel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 8.81Β means the company has $8.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 8.808. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.808. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.808TTM8.8080.000
TTM8.808YOY7.438+1.370
TTM8.8085Y9.916-1.108
5Y9.91610Y9.743+0.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8083.659+5.149
TTM8.8083.834+4.974
YOY7.4384.141+3.297
3Y8.8284.661+4.167
5Y9.9165.756+4.160
10Y9.7436.151+3.592
4.4.3.2. Quick Ratio

Measures if Clinuvel is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Quick Ratio of 14.23Β means the company can pay off $14.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 14.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.230TTM14.2300.000
TTM14.230YOY12.237+1.993
TTM14.2305Y15.414-1.184
5Y15.41410Y12.821+2.593
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.2302.799+11.431
TTM14.2303.143+11.087
YOY12.2373.794+8.443
3Y14.4494.307+10.142
5Y15.4145.707+9.707
10Y12.8216.457+6.364
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Clinuvel Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ClinuvelΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Clinuvel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12Β means that Clinuvel assets areΒ financed with 12.2% credit (debt) and the remaining percentage (100% - 12.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.122. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.122TTM0.1220.000
TTM0.122YOY0.150-0.028
TTM0.1225Y0.117+0.004
5Y0.11710Y0.115+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1220.324-0.202
TTM0.1220.347-0.225
YOY0.1500.329-0.179
3Y0.1330.340-0.207
5Y0.1170.349-0.232
10Y0.1150.379-0.264
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Clinuvel is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 13.8% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.138. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.138. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.138TTM0.1380.000
TTM0.138YOY0.177-0.038
TTM0.1385Y0.134+0.005
5Y0.13410Y0.132+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1380.379-0.241
TTM0.1380.435-0.297
YOY0.1770.412-0.235
3Y0.1540.446-0.292
5Y0.1340.460-0.326
10Y0.1320.509-0.377
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Clinuvel generates.

  • Above 15 is considered overpriced butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A PE ratio of 14.46 means the investor is paying $14.46Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 10.338. Based on the earnings, the company is underpriced. +1
  • The MRQ is 14.462. Based on the earnings, the company is underpriced. +1
  • The TTM is 14.462. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD10.338MRQ14.462-4.124
MRQ14.462TTM14.4620.000
TTM14.462YOY-+14.462
TTM14.4625Y23.245-8.784
5Y23.24510Y19.135+4.110
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.338-2.282+12.620
MRQ14.462-2.062+16.524
TTM14.462-2.541+17.003
YOY--3.722+3.722
3Y4.821-3.754+8.575
5Y23.245-6.100+29.345
10Y19.135-6.653+25.788
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 11.704. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 16.373. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 16.373. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD11.704MRQ16.373-4.669
MRQ16.373TTM16.3730.000
TTM16.373YOY-+16.373
TTM16.3735Y-448.048+464.420
5Y-448.04810Y-216.625-231.423
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.704-3.101+14.805
MRQ16.373-2.689+19.062
TTM16.373-3.594+19.967
YOY--4.363+4.363
3Y5.458-5.065+10.523
5Y-448.048-8.478-439.570
10Y-216.625-9.273-207.352
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Clinuvel is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.54 means the investor is paying $2.54Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 1.815. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.539. Based on the equity, the company is underpriced. +1
  • The TTM is 2.539. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.815MRQ2.539-0.724
MRQ2.539TTM2.5390.000
TTM2.539YOY-+2.539
TTM2.5395Y5.076-2.537
5Y5.07610Y8.543-3.467
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8151.932-0.117
MRQ2.5391.848+0.691
TTM2.5392.119+0.420
YOY-2.469-2.469
3Y0.8462.526-1.680
5Y5.0763.667+1.409
10Y8.5434.351+4.192
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Retained Earnings  -80,03721,908-58,13019,727-38,40231,977-6,42636,38929,964
Total Other Income Expense Net -26-1,593-1,618-656-2,274175-2,0994,7722,673



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets231,124
Total Liabilities28,112
Total Stockholder Equity203,011
 As reported
Total Liabilities 28,112
Total Stockholder Equity+ 203,011
Total Assets = 231,124

Assets

Total Assets231,124
Total Current Assets222,064
Long-term Assets9,060
Total Current Assets
Cash And Cash Equivalents 183,868
Short-term Investments 148,668
Net Receivables 26,238
Other Current Assets 1,330
Total Current Assets  (as reported)222,064
Total Current Assets  (calculated)360,105
+/- 138,041
Long-term Assets
Property Plant Equipment 7,720
Intangible Assets 185
Long-term Assets Other 1,020
Long-term Assets  (as reported)9,060
Long-term Assets  (calculated)8,925
+/- 134

Liabilities & Shareholders' Equity

Total Current Liabilities25,212
Long-term Liabilities2,900
Total Stockholder Equity203,011
Total Current Liabilities
Short-term Debt 370
Accounts payable 2,345
Other Current Liabilities 6,646
Total Current Liabilities  (as reported)25,212
Total Current Liabilities  (calculated)9,361
+/- 15,851
Long-term Liabilities
Long-term Liabilities  (as reported)2,900
Long-term Liabilities  (calculated)0
+/- 2,900
Total Stockholder Equity
Common Stock168,802
Retained Earnings 29,964
Accumulated Other Comprehensive Income 4,245
Total Stockholder Equity (as reported)203,011
Total Stockholder Equity (calculated)203,011
+/-0
Other
Cash and Short Term Investments 183,868
Common Stock Shares Outstanding 51,027
Liabilities and Stockholders Equity 231,124
Net Debt -182,989
Short Long Term Debt Total 880



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
15,441
13,769
10,520
8,066
10,247
10,056
17,071
67,825
54,971
41,614
29,507
20,165
15,995
15,815
17,154
13,644
20,138
28,607
42,905
62,345
81,542
108,568
143,950
193,714
231,124
231,124193,714143,950108,56881,54262,34542,90528,60720,13813,64417,15415,81515,99520,16529,50741,61454,97167,82517,07110,05610,2478,06610,52013,76915,441
   > Total Current Assets 
7,995
7,028
4,483
2,748
5,682
5,246
13,917
65,317
53,120
40,594
29,158
19,932
15,807
15,668
17,039
13,575
19,974
28,470
42,269
61,153
75,156
102,848
140,583
189,618
222,064
222,064189,618140,583102,84875,15661,15342,26928,47019,97413,57517,03915,66815,80719,93229,15840,59453,12065,31713,9175,2465,6822,7484,4837,0287,995
       Cash And Cash Equivalents 
7,927
6,981
4,414
2,612
5,480
4,763
8,606
33,842
25,752
21,711
19,415
12,178
12,719
12,569
14,626
10,572
13,845
23,752
36,198
54,269
66,747
82,691
121,509
156,814
183,868
183,868156,814121,50982,69166,74754,26936,19823,75213,84510,57214,62612,56912,71912,17819,41521,71125,75233,8428,6064,7635,4802,6124,4146,9817,927
       Short-term Investments 
0
0
0
0
0
0
2,024
28,512
25,048
16,043
7,588
5,321
454
0
0
0
0
0
0
28,525
41,095
45,550
94,100
132,946
148,668
148,668132,94694,10045,55041,09528,5250000004545,3217,58816,04325,04828,5122,024000000
       Net Receivables 
57
35
30
31
78
137
233
241
616
212
363
974
1,007
1,743
1,585
1,960
4,824
2,966
5,090
3,759
6,350
16,089
16,202
22,215
26,238
26,23822,21516,20216,0896,3503,7595,0902,9664,8241,9601,5851,7431,0079743632126162412331377831303557
       Other Current Assets 
10
13
39
106
124
314
2,474
2,722
1,703
2,628
1,791
1,460
1,627
1,357
828
205
223
510
339
989
772
882
1,039
1,070
1,330
1,3301,0701,0398827729893395102232058281,3571,6271,4601,7912,6281,7032,7222,474314124106391310
   > Long-term Assets 
7,446
6,741
6,037
5,318
4,565
4,810
3,154
2,508
1,851
1,020
349
233
188
146
114
69
165
137
636
1,193
6,386
5,719
3,367
4,096
9,060
9,0604,0963,3675,7196,3861,193636137165691141461882333491,0201,8512,5083,1544,8104,5655,3186,0376,7417,446
       Property Plant Equipment 
94
116
141
147
120
249
222
332
431
357
322
215
179
146
114
69
165
137
169
707
2,389
2,603
2,700
2,851
7,720
7,7202,8512,7002,6032,3897071691371656911414617921532235743133222224912014714111694
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185
185
185
185
185
185
0
0185185185185185185000000000000000000
       Intangible Assets 
7,352
6,624
5,896
5,171
4,445
4,561
2,932
2,176
1,420
663
28
18
9
0
0
0
0
0
0
185
185
185
185
185
185
185185185185185185000000918286631,4202,1762,9324,5614,4455,1715,8966,6247,352
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282
301
3,812
2,931
482
1,060
0
01,0604822,9313,812301282000000000000000000
> Total Liabilities 
124
318
211
535
1,392
2,601
3,082
2,433
3,156
4,563
3,081
3,757
2,358
1,976
1,726
2,439
2,304
3,163
3,489
5,166
7,873
9,830
18,390
29,082
28,112
28,11229,08218,3909,8307,8735,1663,4893,1632,3042,4391,7261,9762,3583,7573,0814,5633,1562,4333,0822,6011,392535211318124
   > Total Current Liabilities 
124
318
211
535
1,370
2,577
3,067
2,428
3,147
4,544
3,040
3,717
2,339
1,946
1,718
2,435
2,288
3,148
3,471
4,960
6,660
8,707
13,732
25,495
25,212
25,21225,49513,7328,7076,6604,9603,4713,1482,2882,4351,7181,9462,3393,7173,0404,5443,1472,4283,0672,5771,370535211318124
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
261
212
258
315
301
370
3703013152582122610000000000000000000
       Accounts payable 
115
183
69
236
1,180
2,346
2,535
1,597
734
2,056
569
1,697
839
184
178
261
231
579
429
1,500
1,430
2,324
259
2,792
2,345
2,3452,7922592,3241,4301,5004295792312611781848391,6975692,0567341,5972,5352,3461,18023669183115
       Other Current Liabilities 
9
135
141
300
191
231
532
831
2,413
2,488
2,471
2,020
1,500
1,762
1,540
2,175
2,057
2,568
3,042
3,199
5,018
6,125
5,878
6,308
6,646
6,6466,3085,8786,1255,0183,1993,0422,5682,0572,1751,5401,7621,5002,0202,4712,4882,4138315322311913001411359
   > Long-term Liabilities 
0
0
0
0
22
24
15
5
9
19
41
40
19
29
8
3
15
15
18
205
1,213
1,123
4,658
3,588
2,900
2,9003,5884,6581,1231,213205181515382919404119951524220000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
3
15
15
18
34
106
78
3,717
2,889
0
02,8893,71778106341815153800000000000000
> Total Stockholder Equity
15,317
13,451
10,310
7,531
8,855
7,454
13,989
65,392
51,815
37,051
26,426
16,408
13,637
13,839
15,428
11,205
17,796
25,386
39,416
57,180
73,669
98,737
125,559
164,631
203,011
203,011164,631125,55998,73773,66957,18039,41625,38617,79611,20515,42813,83913,63716,40826,42637,05151,81565,39213,9897,4548,8557,53110,31013,45115,317
   Common Stock
15,692
15,382
15,382
16,580
25,494
35,123
52,726
112,813
113,222
113,221
113,228
113,339
119,323
126,710
133,567
138,465
146,765
148,413
148,615
151,314
151,849
151,849
151,849
151,849
168,802
168,802151,849151,849151,849151,849151,314148,615148,413146,765138,465133,567126,710119,323113,339113,228113,221113,222112,81352,72635,12325,49416,58015,38215,38215,692
   Retained Earnings 
-374
-1,932
-5,073
-9,050
-16,639
-27,668
-39,890
-49,066
-63,172
-78,337
-88,971
-100,145
-107,507
-114,122
-119,577
-129,958
-133,063
-125,847
-112,681
-95,487
-80,037
-58,130
-38,402
-9,774
29,964
29,964-9,774-38,402-58,130-80,037-95,487-112,681-125,847-133,063-129,958-119,577-114,122-107,507-100,145-88,971-78,337-63,172-49,066-39,890-27,668-16,639-9,050-5,073-1,932-374
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
1
1
0
0
0
0
0
0
0
0
0
0
0
1,438
2,698
4,095
2,820
3,482
1,352
1,850
5,018
12,112
22,556
0
022,55612,1125,0181,8501,3523,4822,8204,0952,6981,43800000000000110



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

All numbers in thousands.




6.6. Income Statements

All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-06-30. All numbers in thousands.

Gross Profit (+$)
totalRevenue88,178
Cost of Revenue-7,733
Gross Profit80,44580,445
 
Operating Income (+$)
Gross Profit80,445
Operating Expense-30,091
Operating Income48,00650,354
 
Operating Expense (+$)
Research Development2,348
Selling General Administrative25,025
Selling And Marketing Expenses-
Operating Expense30,09127,373
 
Net Interest Income (+$)
Interest Income-
Interest Expense-4,454
Other Finance Cost-4,454
Net Interest Income-
 
Pretax Income (+$)
Operating Income48,006
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)50,67945,333
EBIT - interestExpense = 50,679
50,679
40,091
Interest Expense4,454
Earnings Before Interest and Taxes (EBIT)55,13355,133
Earnings Before Interest and Taxes (EBITDA)56,276
 
After tax Income (+$)
Income Before Tax50,679
Tax Provision--
Net Income From Continuing Ops-50,679
Net Income35,636
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses40,172
Total Other Income/Expenses Net2,6730
 

Technical Analysis of Clinuvel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clinuvel. The general trend of Clinuvel is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clinuvel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Clinuvel Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Clinuvel Pharmaceuticals Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 7.22 < 7.22 < 7.22.

The bearish price targets are: 7.22 > 7.22 > 7.22.

Know someone who trades $CLVLF? Share this with them.πŸ‘‡

Clinuvel Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Clinuvel Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Clinuvel Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Clinuvel Pharmaceuticals Ltd. The current macd is 0.02755551.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Clinuvel price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Clinuvel. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Clinuvel price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Clinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartClinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Clinuvel Pharmaceuticals Ltd. The current adx is 37.24.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Clinuvel shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Clinuvel Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Clinuvel Pharmaceuticals Ltd. The current sar is 7.0711316.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Clinuvel Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Clinuvel Pharmaceuticals Ltd. The current rsi is 62.84. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Clinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartClinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Clinuvel Pharmaceuticals Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Clinuvel price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Clinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator ChartClinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Clinuvel Pharmaceuticals Ltd. The current cci is -39.21568627.

Clinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartClinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Clinuvel Pharmaceuticals Ltd. The current cmo is 31.04.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Clinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartClinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Clinuvel Pharmaceuticals Ltd. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Clinuvel Pharmaceuticals Ltd Daily Williams %R ChartClinuvel Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Clinuvel Pharmaceuticals Ltd. The current atr is 0.01010327.

Clinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) ChartClinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Clinuvel Pharmaceuticals Ltd. The current obv is 49,900.

Clinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartClinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Clinuvel Pharmaceuticals Ltd. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Clinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartClinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Clinuvel Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Clinuvel Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.844
Ma 20Greater thanMa 507.237
Ma 50Greater thanMa 1007.102
Ma 100Greater thanMa 2007.235
OpenGreater thanClose7.220
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Clinuvel with someone you think should read this too:
  • Are you bullish or bearish on Clinuvel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Clinuvel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Clinuvel Pharmaceuticals Ltd.

Receive notifications about Clinuvel Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.